Shuang Liu Selected Research

Integrin alphaVbeta3

2/2010	Optical imaging of integrin alphavbeta3 expression with near-infrared fluorescent RGD dimer with tetra(ethylene glycol) linkers.
12/2009	Radiolabeled cyclic RGD peptides as integrin alpha(v)beta(3)-targeted radiotracers: maximizing binding affinity via bivalency.
11/2009	99mTcO(MAG2-3G3-dimer): a new integrin alpha(v)beta(3)-targeted SPECT radiotracer with high tumor uptake and favorable pharmacokinetics.
8/2009	Noninvasive imaging of tumor integrin expression using (18)F-labeled RGD dimer peptide with PEG (4) linkers.
6/2009	(68)Ga-labeled cyclic RGD dimers with Gly3 and PEG4 linkers: promising agents for tumor integrin alphavbeta3 PET imaging.
4/2009	Improving tumor uptake and pharmacokinetics of (64)Cu-labeled cyclic RGD peptide dimers with Gly(3) and PEG(4) linkers.
1/2009	Improving tumor-targeting capability and pharmacokinetics of (99m)Tc-labeled cyclic RGD dimers with PEG(4) linkers.
12/2008	Improving tumor uptake and excretion kinetics of 99mTc-labeled cyclic arginine-glycine-aspartic (RGD) dimers with triglycine linkers.
7/2007	Radiolabeled divalent peptidomimetic vitronectin receptor antagonists as potential tumor radiotherapeutic and imaging agents.
3/2007	Evaluation of a (99m)Tc-labeled cyclic RGD tetramer for noninvasive imaging integrin alpha(v)beta3-positive breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shuang Liu Research Topics

Disease

256	Neoplasms (Cancer) 09/2022 - 03/2002
48	Inflammation (Inflammations) 08/2022 - 07/2003
41	Neoplasm Metastasis (Metastasis) 02/2022 - 09/2004
39	Glioma (Gliomas) 08/2021 - 10/2005
34	Breast Neoplasms (Breast Cancer) 01/2021 - 09/2004
26	Hepatocellular Carcinoma (Hepatoma) 02/2022 - 01/2010
26	Infections 01/2022 - 07/2003
21	Fibrosis (Cirrhosis) 01/2022 - 09/2002
20	Lung Neoplasms (Lung Cancer) 06/2022 - 02/2006
19	Carcinogenesis 08/2021 - 05/2003
15	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 06/2022 - 01/2017
15	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2022 - 12/2013
14	Rheumatoid Arthritis 01/2021 - 10/2014
13	Body Weight (Weight, Body) 08/2022 - 01/2014
12	Hypoxia (Hypoxemia) 01/2021 - 11/2004
11	Leukemia 01/2022 - 02/2002
10	Prostatic Neoplasms (Prostate Cancer) 01/2022 - 02/2008
10	Colorectal Neoplasms (Colorectal Cancer) 11/2021 - 11/2010
10	Adenocarcinoma of Lung 10/2021 - 07/2015
10	Pulmonary Embolism 08/2015 - 08/2004
9	Carcinoma (Carcinomatosis) 08/2022 - 08/2004
9	Insulin Resistance 05/2022 - 01/2011
9	Type 2 Diabetes Mellitus (MODY) 01/2022 - 01/2011
9	Glioblastoma (Glioblastoma Multiforme) 01/2022 - 01/2003
9	Pancreatic Neoplasms (Pancreatic Cancer) 01/2021 - 10/2009
8	Hypertension (High Blood Pressure) 06/2022 - 01/2019
8	Stomach Neoplasms (Stomach Cancer) 03/2022 - 04/2016
8	Uterine Cervical Neoplasms (Cancer of the Cervix) 01/2022 - 01/2016
8	Stroke (Strokes) 01/2022 - 03/2007
8	Liver Cirrhosis (Hepatic Cirrhosis) 10/2021 - 09/2002
8	Alzheimer Disease (Alzheimer's Disease) 01/2021 - 01/2018
8	Necrosis 01/2020 - 01/2013
7	Atherosclerosis 01/2022 - 01/2011
7	Chronic Hepatitis B 01/2022 - 03/2014
7	Asthma (Bronchial Asthma) 02/2021 - 12/2014
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2021 - 08/2015
7	Ischemic Stroke 01/2021 - 06/2017
7	Melanoma (Melanoma, Malignant) 01/2021 - 10/2013
7	Esophageal Squamous Cell Carcinoma 10/2020 - 09/2003
6	Wounds and Injuries (Trauma) 09/2022 - 11/2004
6	Hemorrhage 09/2022 - 01/2013
6	Non-alcoholic Fatty Liver Disease 01/2022 - 05/2013
6	Adenocarcinoma 01/2022 - 11/2008
6	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 01/2016
6	Myocardial Infarction 12/2021 - 10/2016

Drug/Important Bio-Agent (IBA)

58	Proteins (Proteins, Gene)FDA Link 02/2022 - 02/2002
36	Peptides (Polypeptides)IBA 01/2021 - 07/2003
35	IntegrinsIBA 09/2017 - 08/2004
30	Biomarkers (Surrogate Marker)IBA 01/2022 - 07/2010
26	Pharmaceutical PreparationsIBA 06/2022 - 06/2013
25	cyclic arginine-glycine-aspartic acid peptideIBA 06/2019 - 09/2006
23	CytokinesIBA 09/2022 - 05/2010
23	Long Noncoding RNAIBA 03/2022 - 12/2015
22	Biological ProductsIBA 02/2022 - 05/2008
21	Messenger RNA (mRNA)IBA 01/2022 - 02/2002
19	Integrin alphaVbeta3IBA 02/2010 - 08/2003
18	MicroRNAs (MicroRNA)IBA 01/2022 - 01/2013
17	LigandsIBA 09/2022 - 07/2003
16	EnzymesIBA 08/2022 - 10/2008
16	Glucose (Dextrose)FDA LinkGeneric 05/2022 - 07/2014
15	DNA (Deoxyribonucleic Acid)IBA 01/2022 - 02/2008
15	Small Interfering RNA (siRNA)IBA 01/2022 - 11/2004
15	arginyl-glycyl-aspartic acidIBA 03/2019 - 09/2004
13	ErbB Receptors (EGF Receptor)IBA 06/2022 - 01/2003
12	tricineIBA 09/2013 - 11/2005
11	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2022 - 03/2006
10	RNA (Ribonucleic Acid)IBA 03/2022 - 12/2016
10	GlucocorticoidsIBA 01/2022 - 12/2013
10	AcidsIBA 09/2013 - 11/2005
9	Liposomes (Liposome)IBA 08/2022 - 01/2017
9	Phosphotransferases (Kinase)IBA 02/2022 - 02/2006
9	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2022 - 04/2015
9	Oxygen (Dioxygen)IBA 01/2022 - 10/2008
9	ArsenicIBA 01/2021 - 02/2016
9	ChromatinIBA 01/2020 - 04/2013
9	triphenylphosphineIBA 09/2013 - 11/2005
8	AntigensIBA 12/2022 - 03/2014
8	Cisplatin (Platino)FDA LinkGeneric 06/2022 - 04/2015
8	Triglycerides (Triacylglycerol)IBA 05/2022 - 01/2011
8	Therapeutic UsesIBA 02/2022 - 03/2004
8	Insulin (Novolin)FDA Link 01/2022 - 01/2011
8	Transcription Factors (Transcription Factor)IBA 01/2021 - 09/2014
8	LipidsIBA 01/2021 - 01/2011
8	InterleukinsIBA 01/2021 - 05/2016
8	Radioisotopes (Radionuclides)IBA 12/2012 - 08/2004
7	CollagenIBA 06/2022 - 07/2012
7	CholesterolIBA 05/2022 - 09/2014
7	Anti-Bacterial Agents (Antibiotics)IBA 04/2022 - 10/2014
7	AntioxidantsIBA 01/2022 - 03/2010
7	Antiviral Agents (Antivirals)IBA 10/2021 - 10/2010
7	CationsIBA 12/2012 - 10/2007
7	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 11/2011 - 09/2004
6	AntibodiesIBA 01/2022 - 11/2014
6	InflammasomesIBA 01/2022 - 01/2016
6	CateninsIBA 11/2021 - 11/2010

Therapy/Procedure

97	Therapeutics 08/2022 - 08/2004
21	Drug Therapy (Chemotherapy) 06/2022 - 12/2009
13	Radiotherapy 03/2022 - 08/2003
11	Immunotherapy 06/2022 - 12/2017
6	Transplantation 02/2022 - 08/2009